Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma — Bernard Hobeika (2024) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma
Shared by
Michael Karin
University of California, San Diego
202P The impact of statins and proton-pump inhibitors on immune checkpoint inhibition in patients with hepatocellular carcinoma
Article
2024
en
Authors
+10 more
BH
Bernard Hobeika
AP
A. Philipp
IP
Ignazio Piseddu
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2024
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
Linda Y. Wu
,
Sarah Cappuyns
,
Amanda S. Loh
,
Sean Sun
,
Sara Lewis
,
Max W. Sung
,
Myron Schwartz
,
Josep M. Llovet
,
Deirdre Jill Cohen
BJC Reports
Article
2020
Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma
Naoshi Nishida
,
Masatoshi Kudo
Article
2020
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann‐Lii Cheng
,
Chiun Hsu
,
Stephen L. Chan
,
Su Pin Choo
,
Masatoshi Kudo
Article
2017
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Masatoshi Kudo
Article
2016
Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors
Masatoshi Kudo
Discussion(0)
No comments yet. Be the first to comment.